Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. (NASDAQ: NTRB, NTRBW) is a developer of prescription transdermal pharmaceutical products, with a primary focus on its AVERSA abuse-deterrent transdermal technology and its lead product candidate, an abuse-deterrent fentanyl patch. The Nutriband news stream highlights how the company is advancing this technology platform, interacting with regulators, and managing its corporate structure to support product development.
Readers of the Nutriband news page can follow regulatory and clinical development updates, including the company’s reported meetings with the U.S. Food and Drug Administration on the Chemistry, Manufacturing, and Controls plans and the 505(b)(2) NDA pathway for AVERSA Fentanyl. News items also cover Nutriband’s summaries of FDA feedback on in vitro studies to characterize abuse-deterrent properties and its intention to move toward an IND filing in support of a Human Abuse Potential clinical study.
The company’s releases also describe intellectual property developments, such as a provisional patent application to enhance AVERSA technology and U.S. patent actions related to abuse and misuse deterrent transdermal systems, alongside references to a broad patent portfolio covering AVERSA in multiple countries. Corporate and capital markets news includes announcements of a preferred stock dividend tied to future FDA approval of AVERSA Fentanyl, the sale of a majority stake in subsidiary Pocono Pharmaceutical to EarthVision Bio, and Nutriband’s inclusion in Russell indexes.
Additional coverage includes partnership and collaboration news, such as agreements with Kindeva Drug Delivery for product development, Brand Institute for commercial brand name creation, and a non-binding Letter of Intent with the Qvanta Group to explore advanced technology support for abuse-deterrent pharmaceutical innovation. Investors and observers can use this page to review how Nutriband presents its progress on AVERSA Fentanyl, its stance on issues like illicit versus prescription fentanyl, and its participation in investor conferences and public communications.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has been invited to speak at the 2023 Transdermal and Microneedle Conference in London on January 23-24. CEO Gareth Sheridan will present on improving transdermal technologies to reduce the abuse potential of medications, referencing their AVERSA technology. Additionally, COO Dr. Alan Smith will participate in a panel discussion on microneedles as a drug delivery tool. Other notable participants include representatives from Merck, GSK, and Sanofi.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced progress in collaboration with Kindeva Drug Delivery for their AVERSA™ Fentanyl patch, an abuse-deterrent transdermal system. Recent studies confirm that Nutriband's aversive coating can be produced with standard manufacturing processes, crucial for product development. The product has a projected peak annual sales potential of $80M - $200M within five years post-launch. Nutriband aims to finalize product configuration and transfer technology to Kindeva's commercial facility in California.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has initiated the application process for a dual listing on Upstream, a digital trading app. This move aims to tap into a global investor base, facilitating trades in USDC digital currency and traditional payment methods. CEO Gareth Sheridan emphasized that this listing could enhance shareholder value and liquidity while expanding access to international markets. Approval from MERJ Exchange is pending; however, Nutriband's adherence to NASDAQ standards is sufficient for compliance. The company is known for developing abuse deterrent technologies for pharmaceuticals.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) will be featured on the RedChip Money Report airing on Bloomberg TV this Saturday, September 17, at 7 p.m. ET. The interview will highlight various aspects of the company, including expanded patents, commercialization plans, and Q2 revenue results. Chairman & President Serguei Melnik will discuss these developments, which could pique investor interest. Bloomberg TV reaches approximately 73 million homes across the U.S.
Nutriband Inc. (NASDAQ:NTRB) reported significant growth in its Q2 2022 financial results, achieving record quarterly revenue of $0.5 million, a 113% increase year-over-year. Over six months, revenue rose 44%. The company received a favorable court ruling enabling the cancellation of 1.2 million shares, representing 15% of outstanding shares at the time. Nutriband continues to expand its AVERSA™ intellectual property, now protected in 45 countries. However, net loss increased to $1.0 million from $0.5 million year-over-year.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced the effective date of a 7:6 forward stock split that took place on August 12, 2022, with a record date of August 15, 2022. Each holder of 6 shares of common stock received 7 shares, with no change to the per-share par value. The stock split will not affect stockholders' equity percentages. Additionally, the exercise price of outstanding warrants will be adjusted to $6.43 per share, corresponding to the stock split ratio. Book-entry holders do not need to take action, while those seeking stock certificates will receive further instructions.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced the receipt of a Notice of Allowance for its patent application from the Canadian Intellectual Property Office. This patent is crucial for the company's AVERSA™ transdermal abuse deterrent technology, enhancing intellectual property protection across North America.
The AVERSA™ technology aims to reduce drug misuse and abuse while ensuring accessibility for patients in need. The lead product, AVERSA™ Fentanyl, is projected to achieve peak annual sales of $80M - $200M. Nutriband's patent portfolio spans multiple countries, bolstering its market position.
Nutriband Inc. (NTRB, NTRBW) announced a 7:6 forward stock split effective at 12:01 AM on August 15, 2022. Shareholders will receive seven shares for every six shares held, maintaining the par value. CEO Gareth Sheridan emphasized the company's commitment to creating shareholder value following recent milestones. Nutriband is focused on developing transdermal pharmaceutical products, notably an abuse deterrent fentanyl patch utilizing its AVERSA technology. The company acknowledges various risks involved in its development and regulatory processes.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced a favorable Final Judgment allowing the cancellation of 1.2 million shares, approximately 15% of its outstanding shares, previously issued for an acquisition now rescinded. This cancellation, expected to be processed within one business day, will reduce Nutriband's total outstanding shares to 6.6 million. The company is focused on developing transdermal pharmaceutical products, including its lead product, an abuse deterrent fentanyl patch utilizing the AVERSA technology.
Nutriband Inc. (NASDAQ:NTRB, NASDAQ:NTRBW) has announced the opening of a new branch in Quito, Ecuador, aimed at expanding its product offerings in the region through product registration and contract services. CEO Gareth Sheridan emphasized this move as a significant step towards enhancing revenue opportunities and building relationships. The company specializes in developing transdermal pharmaceutical products, notably an abuse deterrent fentanyl patch utilizing AVERSA® technology. This expansion marks a strategic initiative to penetrate the South American market.
FAQ
What is the current stock price of Nutriband (NTRB)?
What is the market cap of Nutriband (NTRB)?
